News
MHRA (UK) approves Roclanda for the reduction of elevated intraocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension.-Aerie Pharma
Aerie Pharmaceuticals, Inc. announced that Roclanda 50 micrograms/ml + 200 micrograms/ml Eye Drops, Solution (latanoprost + netarsudil) has received marketing authorisation from the Medicines and Healthcare Products Regulatory Agency (MHRA) in Great Britain.
Roclanda is indicated for the reduction of elevated intraocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient IOP reduction. Roclanda was granted a marketing authorisation by the European Commission in January 2021 for the same indication.
Condition: Glaucoma
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins